plerixafor has been researched along with Alloxan Diabetes in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (13.33) | 29.6817 |
| 2010's | 10 (66.67) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, J; Liu, K; Sun, T; Wang, J; Wang, S; Wang, T; Xu, W | 1 |
| Huang, J; Li, T; Li, Y; Lu, H; Sui, M; Wang, S; Zeng, L; Zhang, P | 1 |
| Binda, NS; Cecilia, FS; da Silva Junior, CA; da Silva, JF; de Castro Junior, CJ; Diniz, DM; do Nascimento Cordeiro, M; Ferreira, J; Gomez, MV; Pereira, EMR | 1 |
| Cardier, J; Diaz-Solano, D; Gledhill, T; Gomez, Y; Wittig, O | 1 |
| Chen, M; Deng, X; Han, X; Liu, H; Wang, N; Yan, W | 1 |
| Cai, L; Cui, J; Li, C; Li, W; Li, X; Li, Y; Tan, Y; Wang, G; Xi, S; Yan, X; Zhao, Y | 1 |
| Allen, RJ; Haberman, ID; Lin, CD; Nguyen, PD; Saadeh, PB; Schachar, J; Soares, MA; Szpalski, C; Warren, SM | 1 |
| Advani, A; Advani, SL; Alghamdi, TA; Batchu, SN; Chen, LH; Connelly, KA; Gibson, IW; Marsden, PA; Siddiqi, FS; Sood, MM; Thai, K; White, KE | 1 |
| Abadeh, A; Advani, A; Advani, SL; Connelly, KA; Desjardins, JF; Gilbert, RE; Kabir, G; Mitchell, M; Thai, K; Zhang, Y | 1 |
| Allen, RJ; Carr, J; Chang, CC; Gupta, SM; Levine, JP; Lin, CD; Saadeh, PB; Tanaka, R; Tepper, OM; Warren, SM | 1 |
| Abdi, R; Capella, C; Carvello, M; D'Addio, F; Fiorina, P; Godwin, JG; Jurewicz, M; Kovarik, J; La Rosa, S; Law, K; Petrelli, A; Rodig, S; Sayegh, MH; Thoma, G; Tian, Z; Vergani, A; Wu, E; Zerwes, HG | 1 |
| Asai, J; Hamada, H; Ii, M; Ito, A; Jujo, K; Kamide, C; Katoh, N; Kenny, J; Kishimoto, S; Losordo, DW; Millay, M; Misener, S; Nishimura, Y; Qin, G; Renault, MA; Sekiguchi, H; Takenaka, H; Thorne, T | 1 |
| Wang, XX; Warren, S | 1 |
| Fricker, S; Jiao, C; Schatteman, GC | 1 |
| Aboumrad, E; Madec, AM; Thivolet, C | 1 |
15 other study(ies) available for plerixafor and Alloxan Diabetes
| Article | Year |
|---|---|
Saxagliptin alleviates erectile dysfunction through increasing stromal cell-derived factor-1 in diabetes mellitus.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Erectile Dysfunction; Humans; Male; Penis; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Stromal Cells | 2023 |
SOCS3 inhibits the mesenchymal stromal cell secretory factor SDF-1-mediated improvement of islet function in non-obese diabetic mice.
Topics: Animals; Blood Glucose; Chemokine CXCL12; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Graft Survival; Ligands; Mesenchymal Stem Cells; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Receptors, G-Protein-Coupled; Suppressor of Cytokine Signaling 3 Protein | 2023 |
The inhibitory effect of Phα1β toxin on diabetic neuropathic pain involves the CXCR4 chemokine receptor.
Topics: Analgesics; Animals; Benzylamines; Calcium; Calcium Channels; Chemokine CXCL12; Cyclams; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Heterocyclic Compounds; omega-Conotoxins; Rats; Rats, Wistar; Receptors, CXCR4; Spider Venoms | 2020 |
The effect of G-CSF and AMD3100 on mice treated with streptozotocin: Expansion of alpha-cells and partial islet protection.
Topics: Animals; Benzylamines; Blood Glucose; Cyclams; Diabetes Mellitus, Experimental; Glucagon-Secreting Cells; Granulocyte Colony-Stimulating Factor; Heterocyclic Compounds; Hyperglycemia; Insulin; Insulin-Secreting Cells; Islets of Langerhans; Male; Mice; Streptozocin | 2017 |
CXCR4 antagonist delivery on decellularized skin scaffold facilitates impaired wound healing in diabetic mice by increasing expression of SDF-1 and enhancing migration of CXCR4-positive cells.
Topics: Acellular Dermis; Animals; Benzylamines; Cell Movement; Chemokine CXCL12; Cyclams; Diabetes Mellitus, Experimental; Granulation Tissue; Heterocyclic Compounds; Male; Mice; Receptors, CXCR4; Structure-Activity Relationship; Wound Healing; Wounds and Injuries | 2017 |
A novel mechanism by which SDF-1β protects cardiac cells from palmitate-induced endoplasmic reticulum stress and apoptosis via CXCR7 and AMPK/p38 MAPK-mediated interleukin-6 generation.
Topics: Adenylate Kinase; Animals; Apoptosis; Benzylamines; Cell Line; Chemokine CXCL12; Cyclams; Diabetes Mellitus, Experimental; Diet, High-Fat; Endoplasmic Reticulum Stress; Heterocyclic Compounds; Interleukin-6; Male; NADPH Oxidases; p38 Mitogen-Activated Protein Kinases; Palmitic Acid; Phosphorylation; Rats; Rats, Wistar; Receptors, CXCR; Receptors, CXCR4; Signal Transduction | 2013 |
Combination therapy accelerates diabetic wound closure.
Topics: Animals; Becaplermin; Benzylamines; Cyclams; Diabetes Complications; Diabetes Mellitus, Experimental; Disease Models, Animal; Heterocyclic Compounds; Mice; Neovascularization, Physiologic; Proto-Oncogene Proteins c-sis; Skin Ulcer; Stem Cells; Wound Healing; Wounds and Injuries | 2014 |
CXCR4 promotes renal tubular cell survival in male diabetic rats: implications for ligand inactivation in the human kidney.
Topics: Albuminuria; Animals; Benzylamines; Cell Survival; Chemokine CXCL12; Cyclams; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Epithelial Cells; Gene Expression Regulation; Heterocyclic Compounds; Humans; Kidney Tubules; Male; Matrix Metalloproteinase 9; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Real-Time Polymerase Chain Reaction; Receptors, CXCR; Receptors, CXCR4 | 2015 |
Dipeptidyl peptidase-4 inhibition improves cardiac function in experimental myocardial infarction: Role of stromal cell-derived factor-1α.
Topics: Adamantane; Animals; Benzylamines; Cardiac Catheterization; Chemokine CXCL12; Cyclams; Diabetes Mellitus, Experimental; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Echocardiography; Glucagon-Like Peptide-1 Receptor; Heterocyclic Compounds; Hypoglycemic Agents; Liraglutide; Male; Myocardial Infarction; Rats; Rats, Inbred F344 | 2016 |
Decreased circulating progenitor cell number and failed mechanisms of stromal cell-derived factor-1alpha mediated bone marrow mobilization impair diabetic tissue repair.
Topics: Animals; Benzylamines; Bone Marrow Cells; Cell Count; Chemokine CXCL2; Chemotaxis; Cyclams; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Heterocyclic Compounds; Ischemia; Mice; Mice, Inbred C57BL; Skin; Stem Cells; Surgical Flaps; Wound Healing; Wounds and Injuries | 2010 |
Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1.
Topics: Animals; B7-1 Antigen; B7-H1 Antigen; Benzylamines; Chemokine CXCL12; Chemotaxis, Leukocyte; Cyclams; Diabetes Mellitus, Experimental; Gene Targeting; Graft Survival; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Islets of Langerhans Transplantation; Male; Membrane Glycoproteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Knockout; Peptides; Receptors, CXCR4; Transplantation, Homologous | 2011 |
CXCR4 antagonist AMD3100 accelerates impaired wound healing in diabetic mice.
Topics: Animals; Benzylamines; Capillaries; Cell Movement; Cell Proliferation; Cells, Cultured; Chemokine CXCL12; Collagen; Cyclams; Diabetes Mellitus, Experimental; Female; Fibroblasts; Heterocyclic Compounds; Macrophages; Mice; Mice, Inbred C57BL; Neovascularization, Physiologic; Phagocytosis; Proto-Oncogene Proteins c-sis; Receptors, CXCR4; Receptors, Leptin; Skin; Stem Cells; Treatment Outcome; Wound Healing | 2012 |
[Effect of endothelial progenitor cells mobilization on the healing of calvarial defect in diabetic mice].
Topics: Animals; Benzylamines; Bone Regeneration; Cyclams; Diabetes Mellitus, Experimental; Endothelial Cells; Endothelium, Vascular; Heterocyclic Compounds; Male; Mice; Mice, Inbred C57BL; Osteoblasts; Parietal Bone; Skull; Stem Cells; Wound Healing | 2011 |
The chemokine (C-X-C motif) receptor 4 inhibitor AMD3100 accelerates blood flow restoration in diabetic mice.
Topics: Animals; Antigens, CD34; Benzylamines; Blood Flow Velocity; Cyclams; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Heterocyclic Compounds; Humans; Ischemia; Kinetics; Leukocyte Transfusion; Mice; Receptors, CXCR4 | 2006 |
The CXCR4/CXCL12 (SDF-1) signalling pathway protects non-obese diabetic mouse from autoimmune diabetes.
Topics: Adoptive Transfer; Animals; Autoimmune Diseases; Benzylamines; Cells, Cultured; Chemokine CXCL12; Chemokines, CXC; Cyclams; Cytokines; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Female; Heterocyclic Compounds; Islets of Langerhans; Lymph Nodes; Male; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Receptors, CXCR4; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Th2 Cells | 2007 |